[go: up one dir, main page]

GB2521356B - Antibodies for use in treating conditions related to specific PCKS9 variants and associated diagnostic methods - Google Patents

Antibodies for use in treating conditions related to specific PCKS9 variants and associated diagnostic methods

Info

Publication number
GB2521356B
GB2521356B GB1322253.4A GB201322253A GB2521356B GB 2521356 B GB2521356 B GB 2521356B GB 201322253 A GB201322253 A GB 201322253A GB 2521356 B GB2521356 B GB 2521356B
Authority
GB
United Kingdom
Prior art keywords
pcks9
antibodies
variants
specific
diagnostic methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB1322253.4A
Other versions
GB201322253D0 (en
GB2521356A (en
Inventor
Clube Jasper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kymab Ltd
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kymab Ltd filed Critical Kymab Ltd
Priority to GB1804143.4A priority Critical patent/GB2558442B/en
Priority to GB1322253.4A priority patent/GB2521356B/en
Publication of GB201322253D0 publication Critical patent/GB201322253D0/en
Priority to EP14172578.8A priority patent/EP2886557A1/en
Priority to EP14172579.6A priority patent/EP2886558A1/en
Priority to IES20140280A priority patent/IES86602B2/en
Priority to IES20140279A priority patent/IES86601B2/en
Priority to DE202014010499.9U priority patent/DE202014010499U1/en
Priority to DE202014010421.2U priority patent/DE202014010421U1/en
Priority to PCT/GB2014/053730 priority patent/WO2015092394A1/en
Priority to PCT/GB2014/053729 priority patent/WO2015092393A2/en
Priority to DE112014005975.7T priority patent/DE112014005975T5/en
Priority to TW103144065A priority patent/TW201525005A/en
Priority to CN201480075772.XA priority patent/CN106062004A/en
Priority to JP2016541434A priority patent/JP6720079B2/en
Priority to TW103144043A priority patent/TWI713444B/en
Priority to DE112014005747.9T priority patent/DE112014005747T5/en
Publication of GB2521356A publication Critical patent/GB2521356A/en
Application granted granted Critical
Publication of GB2521356B publication Critical patent/GB2521356B/en
Priority to JP2020104523A priority patent/JP2020152729A/en
Priority to JP2021155708A priority patent/JP7202431B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GB1322253.4A 2013-12-17 2013-12-17 Antibodies for use in treating conditions related to specific PCKS9 variants and associated diagnostic methods Active GB2521356B (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
GB1804143.4A GB2558442B (en) 2013-12-17 2013-12-17 Antibodies for use in treating conditions related to specific PCSK9 variants and associated diagnostic methods
GB1322253.4A GB2521356B (en) 2013-12-17 2013-12-17 Antibodies for use in treating conditions related to specific PCKS9 variants and associated diagnostic methods
EP14172578.8A EP2886557A1 (en) 2013-12-17 2014-06-16 Antibodies for use in treating conditions related to specific PCSK9 variants in specific patient populations
EP14172579.6A EP2886558A1 (en) 2013-12-17 2014-06-16 Antibodies for use in treating conditions related to specific PCSK9 variants in specific patient populations
IES20140280A IES86602B2 (en) 2013-12-17 2014-11-07 An injectable antibody preparation for use in reducing or maintaining previously reduced cholesterol level
IES20140279A IES86601B2 (en) 2013-12-17 2014-11-07 An injectable antibody preparation for use in reducing or maintaining previously reduced cholesterol level
DE202014010499.9U DE202014010499U1 (en) 2013-12-17 2014-12-14 Targeting of human PCSK9 for cholesterol treatment
DE112014005975.7T DE112014005975T5 (en) 2013-12-17 2014-12-17 Human goals
TW103144043A TWI713444B (en) 2013-12-17 2014-12-17 Human targets
PCT/GB2014/053729 WO2015092393A2 (en) 2013-12-17 2014-12-17 Human targets
DE202014010421.2U DE202014010421U1 (en) 2013-12-17 2014-12-17 Human goals
TW103144065A TW201525005A (en) 2013-12-17 2014-12-17 Targeting human PCSK9 for cholesterol treatment
CN201480075772.XA CN106062004A (en) 2013-12-17 2014-12-17 Ligands specifically binding to human targets of interest
JP2016541434A JP6720079B2 (en) 2013-12-17 2014-12-17 A ligand that specifically binds to a human target of interest
PCT/GB2014/053730 WO2015092394A1 (en) 2013-12-17 2014-12-17 Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
DE112014005747.9T DE112014005747T5 (en) 2013-12-17 2014-12-17 Antibodies for use in the treatment of conditions related to specific PCSK9 variants in specific patient populations
JP2020104523A JP2020152729A (en) 2013-12-17 2020-06-17 Ligands that specifically bind to human targets of interest
JP2021155708A JP7202431B2 (en) 2013-12-17 2021-09-24 Ligands that specifically bind to human targets of interest

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1322253.4A GB2521356B (en) 2013-12-17 2013-12-17 Antibodies for use in treating conditions related to specific PCKS9 variants and associated diagnostic methods

Publications (3)

Publication Number Publication Date
GB201322253D0 GB201322253D0 (en) 2014-01-29
GB2521356A GB2521356A (en) 2015-06-24
GB2521356B true GB2521356B (en) 2018-10-10

Family

ID=50031010

Family Applications (2)

Application Number Title Priority Date Filing Date
GB1804143.4A Active GB2558442B (en) 2013-12-17 2013-12-17 Antibodies for use in treating conditions related to specific PCSK9 variants and associated diagnostic methods
GB1322253.4A Active GB2521356B (en) 2013-12-17 2013-12-17 Antibodies for use in treating conditions related to specific PCKS9 variants and associated diagnostic methods

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB1804143.4A Active GB2558442B (en) 2013-12-17 2013-12-17 Antibodies for use in treating conditions related to specific PCSK9 variants and associated diagnostic methods

Country Status (1)

Country Link
GB (2) GB2558442B (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004097047A1 (en) * 2003-04-25 2004-11-11 Institut National de la Santé et de la Recherche Médicale Mutations in the human pcsk9 gene associated to hypercholesterolemia
WO2008105797A2 (en) * 2006-06-30 2008-09-04 Bristol-Myers Squibb Company Polynucleotides encoding novel pcsk9 variants
WO2009026558A1 (en) * 2007-08-23 2009-02-26 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
WO2012054438A1 (en) * 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
WO2012088313A1 (en) * 2010-12-22 2012-06-28 Genentech, Inc. Anti-pcsk9 antibodies and methods of use
WO2013091103A1 (en) * 2011-12-20 2013-06-27 Adaerata, Limited Partnership Single domain antibodies as inhibitors of pcsk9

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004097047A1 (en) * 2003-04-25 2004-11-11 Institut National de la Santé et de la Recherche Médicale Mutations in the human pcsk9 gene associated to hypercholesterolemia
WO2008105797A2 (en) * 2006-06-30 2008-09-04 Bristol-Myers Squibb Company Polynucleotides encoding novel pcsk9 variants
EP2671946A1 (en) * 2006-06-30 2013-12-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
WO2009026558A1 (en) * 2007-08-23 2009-02-26 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
WO2012054438A1 (en) * 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
WO2012088313A1 (en) * 2010-12-22 2012-06-28 Genentech, Inc. Anti-pcsk9 antibodies and methods of use
WO2013091103A1 (en) * 2011-12-20 2013-06-27 Adaerata, Limited Partnership Single domain antibodies as inhibitors of pcsk9

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Clinical Science, Vol 113, 2007, M Scartezini et al, "The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy UK men", 435-441 *
Journal of the American College of Cardiology, Vol 45, 2005, SN Chen et al, "A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker...", 1611-1619 *
Lipids in Health and Disease, Vol 12, 2013, J Mayne et al, "Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations", 70 *

Also Published As

Publication number Publication date
GB201804143D0 (en) 2018-05-02
GB2558442A (en) 2018-07-11
GB201322253D0 (en) 2014-01-29
GB2521356A (en) 2015-06-24
GB2558442B (en) 2018-10-24

Similar Documents

Publication Publication Date Title
IL290547A (en) Antibodies and methods of use
HUE039560T2 (en) Microclosures and related methods for skin treatment
IL244495B (en) Anti-alpha-synuclein antibodies and methods of use
ZA201501858B (en) Anti-mcam antibodies and associated methods of use
ZA201406967B (en) Anti sez6 antibodies and methods of use
GB2516343B (en) Improvements in and relating to ophthalmoscopes
SG11201601471SA (en) Diagnostic methods and compositions for treatment of glioblastoma
PL3004833T3 (en) Improvements in and relating to tissue sampling
GB201305822D0 (en) Improvements in and relating to apparatus and methods
IL244643A0 (en) Anti-ly6e antibodies and methods of use
SG11201510021TA (en) Compositions and methods for use in medical diagnosis
EP2972796A4 (en) Methods and apparatus to manage concurrent predicate expressions
SG11201510300RA (en) Compositions and methods for treating skin
GB2522177B (en) Improvements in and relating to sampling
GB201318468D0 (en) Improvements in and relating to processing methods and processing apparatus
GB201318482D0 (en) Improvements in and relating to apparatus for stirring and methods of stirring
GB2521356B (en) Antibodies for use in treating conditions related to specific PCKS9 variants and associated diagnostic methods
GB201300540D0 (en) Improvements in and relating to stimulating needles
GB201303203D0 (en) Improvements in and relating to storage apparatus
GB201302884D0 (en) Novel methods for diagnosis and therapy
GB201304148D0 (en) Improvements in or relating to treatment apparatus
GB201300385D0 (en) Methods relating to wool treatment
GB201322489D0 (en) Improvement in and relating to waveguides
GB201322488D0 (en) Improvements in and relating to waveguides